D012958OrganizationsN03.540.828.838Societies, Scientificprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfConnectionsnumber of connectionsprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierInformation Resourcevivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConcept0.1851640.07573322subject area for17198289DeBruin DA, Scholder SL, Kahn J, Mastroianni AC, Marshall MF, Lantos J, Sugarman JAcademic medicine : journal of the Association of American Medical CollegesDeBruin DA, Scholder SL, Kahn J, Mastroianni AC, Marshall MF, Lantos J, Sugarman J. Educational approaches to the responsible conduct of clinical research: an exploratory study. Acad Med. 2007 Jan; 82(1):32-9.Acad Med2007-01-01T00:00:002007Educational approaches to the responsible conduct of clinical research: an exploratory study.31762152Shakhnovich V, Meibohm B, Rosenberg A, Kierzek AM, Hasenkamp R, Funk RS, Thalhauser CJ, van der Graaf PH, Wang YC, Hamuro LClinical and translational scienceShakhnovich V, Meibohm B, Rosenberg A, Kierzek AM, Hasenkamp R, Funk RS, Thalhauser CJ, van der Graaf PH, Wang YC, Hamuro L. Immunogenicity in Clinical Practice and Drug Development: When is it Significant? Clin Transl Sci. 2020 03; 13(2):219-223.Clin Transl Sci2019-11-25T00:00:002019Immunogenicity in Clinical Practice and Drug Development: When is it Significant?